Search research articles
Contact Us
Filters
Showing results (91-100 of 302) with videos related to
Page
of 31
Sort By:
Expert Opinion on Drug Safety
|
June 5, 2019
Benefits versus risk profile of buparlisib for the treatment of breast cancer
Anne Patsouris, Paule Augereau, Jean-Sebastien Frenel, et al.
Breast Cancer (Tokyo, Japan)
|
May 22, 2024
Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype
Pascal Jézéquel, Hamza Lasla, Wilfried Gouraud, et al.
Cancer Chemotherapy and Pharmacology
|
February 20, 2007
Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients
Mario Campone, Jeany M Rademaker-Lakhai, Jaafar Bennouna, et al.
Cell Death & Disease
|
September 14, 2022
Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties
Thomas L Bonneaud, Chloé C Lefebvre, Lisa Nocquet, et al.
The Breast Journal
|
March 27, 2013
A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines
Mario Campone, Natalya Dobrovolskaya, Serjei Tjulandin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2010
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial
Catherine Van Poznak, Rosemary A Hannon, John R Mackey, et al.
Asia-Pacific Journal of Clinical Oncology
|
April 20, 2010
Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases
Mark A Rosenthal, Peter Davidson, Frederic Rolland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2010
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab
Fabrice Andre, Mario Campone, Ruth O'Regan, et al.
Scientific Reports
|
June 6, 2020
Impact of pemetrexed chemotherapy on the gut microbiota and intestinal inflammation of patient-lung-derived tumor xenograft (PDX) mouse models
Cindy Pensec, Florence Gillaizeau, Dominique Guenot, et al.
Journal of Extracellular Biology
|
December 18, 2024
Monitoring concentration and lipid signature of plasma extracellular vesicles from HR<sup>+</sup> metastatic breast cancer patients under CDK4/6 inhibitors treatment
Mathilde Richard, Rosalie Moreau, Mikaël Croyal, et al.
Page
of 31
Search research articles
Search
Showing results (91-100 of 302) with videos related to
Sort By:
Page
of 31
Expert Opinion on Drug Safety
|
June 5, 2019
Benefits versus risk profile of buparlisib for the treatment of breast cancer
Anne Patsouris, Paule Augereau, Jean-Sebastien Frenel, et al.
Breast Cancer (Tokyo, Japan)
|
May 22, 2024
Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype
Pascal Jézéquel, Hamza Lasla, Wilfried Gouraud, et al.
Cancer Chemotherapy and Pharmacology
|
February 20, 2007
Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients
Mario Campone, Jeany M Rademaker-Lakhai, Jaafar Bennouna, et al.
Cell Death & Disease
|
September 14, 2022
Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties
Thomas L Bonneaud, Chloé C Lefebvre, Lisa Nocquet, et al.
The Breast Journal
|
March 27, 2013
A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines
Mario Campone, Natalya Dobrovolskaya, Serjei Tjulandin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2010
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial
Catherine Van Poznak, Rosemary A Hannon, John R Mackey, et al.
Asia-Pacific Journal of Clinical Oncology
|
April 20, 2010
Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases
Mark A Rosenthal, Peter Davidson, Frederic Rolland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2010
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab
Fabrice Andre, Mario Campone, Ruth O'Regan, et al.
Scientific Reports
|
June 6, 2020
Impact of pemetrexed chemotherapy on the gut microbiota and intestinal inflammation of patient-lung-derived tumor xenograft (PDX) mouse models
Cindy Pensec, Florence Gillaizeau, Dominique Guenot, et al.
Journal of Extracellular Biology
|
December 18, 2024
Monitoring concentration and lipid signature of plasma extracellular vesicles from HR<sup>+</sup> metastatic breast cancer patients under CDK4/6 inhibitors treatment
Mathilde Richard, Rosalie Moreau, Mikaël Croyal, et al.
Page
of 31